IJMPCERO  Vol.5 No.1 , February 2016
Evaluation of Magnetic Resonance Imaging Findings and Short-Term Outcome in Brain Metastatic Tumors after CyberKnife Treatment
Abstract: Objective: To evaluate the treatments’ outcomes in brain metastatic tumors after CyberKnife treatment according to magnetic resonance imaging (MRI) findings and improvement of symptoms. Methods: A retrospective analysis of CyberKnife treatment; 63 cases of patients with brain metastases; the use of CyberKnife treatment; short-term outcome evaluation after treatment and the MRI findings and measured before treatment and underwent diffusion-weighted imaging MRI scan of apparent diffusion coefficient (ADC) values. Results: 3 months after CyberKnife treatment and effectiveness were 82.5% and 96.8% respectively; 6 months and one year survival rates were 82.5% and 55.6% respectively; the median survival time was 16 months. MRI of 52 patients (67 lesions) ADC values after treatment increased to some extent than before treatment. There are 38 lesions volume to shrink or disappear, no enhancement or slight enhancement in the lesion, no edema zone; 27 lesions does not change in volume, no edema (18 lesions significantly weakened the degree of enhancement; 6 lesions showed no obvious change enhancement; 3 lesions showed ring enhancement, internal cystic); 2 lesions volume were larger, heterogeneous enhancement, peripheral edema. Conclusion: CyberKnife is an effective method for treating brain metastatic tumor. MRI can accurately evaluate tumor lesions after treatment.
Cite this paper: Hu, J. , Tian, H. , Guo, N. , Wang, D. and Sun, J. (2016) Evaluation of Magnetic Resonance Imaging Findings and Short-Term Outcome in Brain Metastatic Tumors after CyberKnife Treatment. International Journal of Medical Physics, Clinical Engineering and Radiation Oncology, 5, 96-99. doi: 10.4236/ijmpcero.2016.51010.

[1]   Therasse, P., Arbuck, S.G., Eisenhauer, E.A., et al. (2000) New Guidelines to Evaluate the Response to Treatment in Solid Tumors. Journal of the National Cancer Institute, 92, 205-216.

[2]   Yu, Z., Yin, W.B., Xu, G.Z., et al. (2008) Radiation Therapy Oncology. 4th Edition, Peking Union Medical College Press, Beijing, 796-798.

[3]   Mori, Y., Kondziolka, D., Flickinger, J.C., Logan, T. and Lunsford, L.D. (1998) Stereotactic Radiosurgery for Brain Metastasis from Renal Cell Carcinoma. Cancer, 83, 344-353.<344::AID-CNCR19>3.0.CO;2-T

[4]   Mori, Y., Kondziolka, D., Flickinger, J.C., Kirkwood, J.M., Agarwala, S. and Lunsford, L.D. (1998) Stereotactic Radiosurgery for Cerebral Metastatic Melanoma: Factors Affecting Local Disease Control and Survival. International Journal of Radiation Oncology, Biology, Physics, 42, 581-589.

[5]   Young, M.M., Medbery, C.A., Morrison, A.E., et al. (2005) Stereotactic Radiosurgery for Brain Metastases from Non-Small Cell Lung Cancer: Comparison of Gamma Knife and CyberKnife. Robotic Radiosurgery, 1, 97-107.

[6]   Nishizaki, T., Saito, K., Jimi, Y., Harada, N., Kajiwara, K., Nomura, S., Ishihara, H., Yoshikawa, K., Yoneda, H., Suzuki, M. and Gibbs, I.C. (2006) The Role of CyberKnife Radiosurgery/Radiotherapy for Brain Metastases of Multiple or Large-Size Tumors. Minimally Invasive Neurosurgery, 49, 203-209.

[7]   Simpson, J.R., Mendenhall, W.M., Schupak, K.D., American College of Radiology, et al. (2000) Follow-Up and Retreatment of Brain Metastasis (ACR Appropriateness Criteria). Radiology, 215, 1129-1135.

[8]   Chernov, M.F., Ono, Y., Abe, K., et al. (2013) Differentiation of Tumor Progression and Radiation-Induced Effects after Intracranial Radiosurgery. In: Hayashi, M., Ganz, J.C., Takakura, K. and Chernov, M.F., Eds., Gamma Knife Neurosurgery in the Management of Intracranial Disorders, Springer, New York, 193-210.

[9]   Asao, C., Korogi, Y., Kitajima, M., Hirai, T., Baba, Y., Makino, K., Kochi, M., Morishita, S. and Yamashita, Y. (2005) Diffusion-Weighted Imaging of Radiation-Induced Brain Injury for Differentiation from Tumor Recurrence. American Journal of Neuroradiology, 26, 1455-1460.